Latest Headlines
CATEGORY
-
2023-03-29PM Lee receives a first-hand update by Biosyngen on its progress in cell therapyThe city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trade and Industry Minister Gan Kim Yong, Health Minister Ong Ye Kung, Senior Minister of State for ForeREAD MORE
-
2024-09-19Biosyngen Presents Pioneering“Conditional Activation + Armor Enhancement” SUPER-T technology at ESMO 2024Barcelona, Spain – September 13-17, 2024 – The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchersREAD MORE
-
2024-09-19Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual MeetingBarcelona, Spain – September 13-17, 2024 – The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchersREAD MORE
-
2024-09-18Biosyngen’s first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial Phase I trial data debut at ESMO 2024 Annual CongressBarcelona, Spain – September 13-17, 2024 – The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchersREAD MORE
-
2024-08-13Biosyngen’s BRG01 Receives FDA Approval for Phase II Clinical TrialBiosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI trials in both the U.S. and China for the treatment of reREAD MORE
-
2024-08-01Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune TherapyBiosyngen has announced a strategic collaboration with Singapore's Agency for Science, Technology and Research (A*STAR) to enhance autoimmune therapy. The partnership was signed during the 14th Meeting of the Singapore-Guangdong Collaboration Council, held at China-Singapore Guangzhou Knowledge CityREAD MORE